SB01 is a new drug originated in Taiwan, from discovery, research and development, preclinical ADME, API and finished product manufactured to the USFDA IND (Investigational New Drug). It is also the first product co-development by stakeholder in the industry, government, educational and research institutes.
SB01 is an injectable anti-cancer NCE.SB01 granted the approval of Industry Technology Development Project and byMinistry of Economic Affairs in 2011. Nowadays, the Phase I clinical trial of SB01 has been conducting in Taiwan.


SB02 was in-licensed from NHRI, it is also a anti-cancer NCE discovery and developed by Taiwanese. SB02 is an anti-cancer NCE anti-cancer through oral route which treats patients who suffer from stomach cancer. Nowadays, the preclinical research is under development in Taiwan.